Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Alison Yu, Shauna Sinclair, Scott Furlan, Steven Bosinger, Victor Tkachev, James Rhodes, Audrey Grizzle Tumlin, Alexandria Narayan, Kayla Cribbin, Scott Gillespie, Ted A Gooley, Marcelo C Pasquini, Kyle Hebert, Urvi Kapoor, Andre Rogatko, Mourad Tighiouart, Sungjin Kim, Catherine Bresee, Sung W Choi, Jeffrey Davis, Christine Duncan, Roger Giller, Michael Grimley, Andrew C Harris, David Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A Pulsipher, Shalini Shenoy, Aleksandra Petrovic, Kirk R Schultz, Gregory A Yanik, Edmund K Waller, John E Levine, James L Ferrara, Bruce R Blazar, Amelia Langston, John T Horan, Leslie S Kean
PURPOSE: Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation. There are no approved agents for AGVHD prevention, underscoring the critical unmet need for novel therapeutics. ABA2 was a phase II trial to rigorously assess safety, efficacy, and immunologic effects of adding T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)-based GVHD prophylaxis, to test whether abatacept could decrease AGVHD...
January 15, 2021: Journal of Clinical Oncology